INZY |
Inozyme Pharma, Inc. |
Oct 3, 2024 |
1 |
$0 |
4 |
Oct 7, 2024 |
Director |
INZY |
Inozyme Pharma, Inc. |
Oct 3, 2024 |
0 |
$0 |
3 |
Oct 7, 2024 |
Director |
DNLI |
Denali Therapeutics Inc. |
May 31, 2024 |
2 |
$0 |
4 |
Jun 4, 2024 |
Director |
RARE |
Ultragenyx Pharmaceutical Inc. |
Mar 1, 2024 |
4 |
-$256K |
4 |
Mar 5, 2024 |
EVP & Chief Commercial Officer |
RARE |
Ultragenyx Pharmaceutical Inc. |
Sep 5, 2023 |
1 |
-$228K |
4 |
Sep 6, 2023 |
EVP & Chief Commercial Officer |
RARE |
Ultragenyx Pharmaceutical Inc. |
Jun 19, 2023 |
1 |
-$14.7K |
4 |
Jun 21, 2023 |
EVP & Chief Commercial Officer |
DNLI |
Denali Therapeutics Inc. |
Jun 1, 2023 |
2 |
$0 |
4 |
Jun 5, 2023 |
Director |
RARE |
Ultragenyx Pharmaceutical Inc. |
Mar 1, 2023 |
4 |
-$166K |
4 |
Mar 3, 2023 |
EVP & Chief Commercial Officer |
RARE |
Ultragenyx Pharmaceutical Inc. |
Jun 19, 2022 |
1 |
-$16.2K |
4 |
Jun 22, 2022 |
EVP & Chief Commercial Officer |
RARE |
Ultragenyx Pharmaceutical Inc. |
Mar 1, 2022 |
3 |
-$181K |
4 |
Mar 3, 2022 |
EVP & Chief Commercial Officer |
DNLI |
Denali Therapeutics Inc. |
Feb 7, 2022 |
0 |
$0 |
3/A |
Feb 14, 2022 |
Director |
DNLI |
Denali Therapeutics Inc. |
Feb 3, 2022 |
2 |
$0 |
4 |
Feb 7, 2022 |
Director |
DNLI |
Denali Therapeutics Inc. |
Feb 3, 2022 |
0 |
$0 |
3 |
Feb 7, 2022 |
Director |
RARE |
Ultragenyx Pharmaceutical Inc. |
Oct 14, 2021 |
1 |
-$24.6K |
4 |
Oct 18, 2021 |
EVP & Chief Commercial Officer |
RARE |
Ultragenyx Pharmaceutical Inc. |
Jul 6, 2021 |
1 |
-$34.3K |
4 |
Jul 8, 2021 |
EVP & Chief Commercial Officer |
RARE |
Ultragenyx Pharmaceutical Inc. |
Jun 19, 2021 |
2 |
-$95.7K |
4 |
Jun 23, 2021 |
EVP & Chief Commercial Officer |
RARE |
Ultragenyx Pharmaceutical Inc. |
May 6, 2021 |
2 |
-$79.6K |
4 |
May 10, 2021 |
EVP & Chief Commercial Officer |